{
    "clinical_study": {
        "@rank": "63775", 
        "arm_group": [
            {
                "arm_group_label": "37.5 mg Phentermine daily for 7 days", 
                "arm_group_type": "Experimental", 
                "description": "In this arm, participants receive 37.5mg phentermine for one week followed by 2 weeks of placebo.\nOther names for phentermine:\nadipex ionamin"
            }, 
            {
                "arm_group_label": "Placebo (for phentermine 37.5mg)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In this arm, participants receive Placebo (for 37.5mg phentermine) for two weeks followed by phentermine 37.5mg for 7 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to determine whether one week of phentermine compared to placebo\n      administration results in changes in food intake during a laboratory meal."
        }, 
        "brief_title": "Studying the Effects of Phentermine on Eating Behavior", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "This study aims to explore whether short-term measures of eating behavior can be related to\n      later, longer-term weight loss. In a double-blind, randomized fashion, participants will be\n      asked to take study medication for three weeks: one week of phentermine and two weeks of\n      placebo. At the end of the first and third weeks, participants will be asked to participate\n      in a range of eating behavior studies. Following this three-week, double-blind phase,\n      participants will be offered 6 months of open treatment for weight loss."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI between 30-40kg/m2\n\n          -  Stable weight (+5 lbs) for a minimum of 3 months\n\n          -  Systolic Blood Pressure <140mm Hg\n\n          -  Diastolic Blood Pressure <90 mm Hg\n\n          -  Pulse <95 beats per minute\n\n          -  English language proficiency\n\n        Exclusion Criteria:\n\n          -  Previous unsuccessful trial of phentermine\n\n          -  Prior adverse reaction to phentermine\n\n          -  On any antidepressant medications,especially monoamine oxidase inhibitors(MAOI)\n\n          -  History of neurological disorder (e.g. dementia)\n\n          -  History of moderate or severe head injury\n\n          -  Current or past history of coronary artery disease\n\n          -  Current or past history of stroke or transient ischemic attack\n\n          -  Current or past history of heart arrhythmias\n\n          -  Current of past history of congestive heart failure\n\n          -  Current or past history of peripheral artery disease\n\n          -  Current or past history of liver disease\n\n          -  Current or past history of kidney disease\n\n          -  Uncontrolled diabetes mellitus (type I or II)\n\n          -  Narrow-angle glaucoma\n\n          -  Hypo- or hyper-thyroidism not adequately treated\n\n          -  On medications (prescribed or OTC) known to affect appetite (e.g. diet pills),\n             weight, or metabolism\n\n          -  Current or past history (within the past 12 months) of major depression\n\n          -  Current or past history (past 12 months) of alcohol or drug abuse or dependence\n\n          -  Current or past history (lifetime) of amphetamine abuse or dependence\n\n          -  Known history of learning disorder or developmental disability\n\n          -  Current or past Attention Deficit Hyperactivity Disorder (ADHD)\n\n          -  Pregnancy, planning to become pregnant, or lactation within the previous 6 months\n\n          -  Waist circumference greater than 188cm\n\n          -  Indwelling metallic object (e.g., pacemaker,pump), non-removable metal jewelry,\n             medicinal patch or recent metallic ink tattoo\n\n          -  Significant claustrophobia\n\n          -  Current or past history of anorexia nervosa,bulimia nervosa (within the past 12\n             months) or binge eating disorder (within the previous 6 months)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886937", 
            "org_study_id": "6415"
        }, 
        "intervention": [
            {
                "arm_group_label": "37.5 mg Phentermine daily for 7 days", 
                "description": "After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.", 
                "intervention_name": "Phentermine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "adipex", 
                    "ionamin"
                ]
            }, 
            {
                "arm_group_label": "Placebo (for phentermine 37.5mg)", 
                "description": "Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "sugar pill"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Phentermine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 24, 2013", 
        "link": {
            "description": "Click here for more information about this study", 
            "url": "http://columbiaeatingdisorders.org/research-obesity.html"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "The New York State Psychiatric Institute at Columbia University Medical Center"
            }, 
            "investigator": {
                "last_name": "Laurel Mayer, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Quantification of Ingestive Behavior", 
        "overall_contact": {
            "email": "edru@nyspi.columbia.edu", 
            "last_name": "Simona Kaplan, BA", 
            "phone": "212-543-5739"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure is the difference in food intake assessed by laboratory meal study after one week of phentermine administration compared to one week of placebo administration.", 
            "measure": "Change in Food intake", 
            "safety_issue": "No", 
            "time_frame": "three weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "New York State Psychiatric Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "New York State Psychiatric Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}